Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository

Overview

Hidradenitis suppurativa (HS) is a common and debilitating skin disease that is poorly understood and understudied. As a result, little is known about disease prognosis and few effective treatments exist for this condition. This prospective observational cohort study aims to comprehensively characterize the clinical and biological features of HS. The results of this research will provide a basis for the development of an HS clinical classification system and identification of potential treatments for HS.

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: September 1, 2029

Clinical Trial Outcome Measures

Primary Measures

  • Primary Objective
    • Time Frame: 2019-2029
    • The primary aim of this study is to identify clinical and biologic characteristics of hidradenitis suppurativa.

Secondary Measures

  • Secondary Objective
    • Time Frame: 2019-2029
    • Secondary aims include correlating alterations in clinical and biological characteristics with disease status, and identifying genetic variants that predict disease progression or response to therapy.

Participating in This Clinical Trial

Inclusion Criteria

1. Male or female ≥ 10 years of age 2. Diagnosis of HS by a dermatologist or practitioner experienced in making a diagnosis of HS 3. Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study. Exclusion Criteria:

1. Inability to give informed consent or unavailability of a parent/guardian who is able and willing to give informed consent.

Gender Eligibility: All

Minimum Age: 10 Years

Maximum Age: N/A

Investigator Details

  • Lead Sponsor
    • University of California, San Francisco
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Haley B Naik, MD, MHSc, FAAD, Principal Investigator, University of California, San Francisco
  • Overall Contact(s)
    • Hannah Balter, 415-502-4741, hannah.balter@ucsf.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.